PRME
HEALTHCAREPrime Medicine, Inc. Common Stock
What's Moving PRME Today?
No stock-specific AI insight has been generated for PRME yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.24
Fundamentals
Trading
PRME News
24 articles- Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)GlobeNewswire·Jun 22, 2026
- Prime Medicine’s CGD therapy gets FDA RMAT, speeding reviewStock Titan·Jun 22, 2026
- Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson DiseaseYahoo Finance·Jun 18, 2026
- Ocular Therapeutix vs. Prime Medicine: A 2026 Analysis of Medical Innovation Stocks - News and StatisticsIndexBox·Jun 15, 2026
- Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?Motley Fool·Jun 15, 2026
- Transcript : Prime Medicine, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 10www.marketscreener.com·Jun 10, 2026
- We're Keeping An Eye On Prime Medicine's (NASDAQ:PRME) Cash Burn RateYahoo Finance·Jun 4, 2026
- Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare ConferenceYahoo Finance·Jun 3, 2026
- Prime Medicine to Present at Jefferies Global Healthcare ConferenceYahoo Finance·May 28, 2026
- Prime Medicine (PRME) Reports Q1 EPSInsider Monkey·May 13, 2026
- Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 7, 2026
- RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseYahoo Finance·May 7, 2026
- Harmony Biosciences Holdings, Inc. (HRMY) Q1 Earnings and Revenues Miss EstimatesYahoo Finance·May 7, 2026
- Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business UpdatesYahoo Finance·May 7, 2026
- Prime Medicine (PRME) Appoints Svetlana Makhni as Chief Financial OfficerYahoo Finance·Apr 23, 2026
- Prime Medicine Appoints Svetlana Makhni as Chief Financial OfficerYahoo Finance·Apr 16, 2026
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First StepBenzinga·Apr 1, 2026
- Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash RunwayYahoo Finance·Mar 8, 2026
- Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 3, 2026
- Prime Medicine Reports Full Year 2025 Financial Results and Provides Business UpdatesYahoo Finance·Mar 3, 2026
- Prime Medicine to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 25, 2026
- Jacob Funds Bets on Prime Medicine (PRME), a Next-Generation Gene Therapy CompanyYahoo Finance·Feb 18, 2026
- Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue EstimatesYahoo Finance·Feb 11, 2026
- Favourable Signals For Prime Medicine: Numerous Insiders Acquired StockYahoo Finance·Jan 27, 2026
All 24 articles loaded
Price Data
52-Week Range
$3.24
Fundamentals
Trading
About Prime Medicine, Inc. Common Stock
Prime Medicine, Inc. is an innovative biotechnology company at the forefront of genetic medicine, leveraging its proprietary Prime Editing technology to achieve precise and targeted DNA modifications. The company has established a comprehensive pipeline designed to tackle serious diseases, encompassing genetic disorders and multiple cancer types, thereby addressing significant unmet medical needs in the healthcare landscape. With a solid intellectual property portfolio and a strategic focus on developing transformative therapeutic solutions, Prime Medicine is well-positioned for robust growth and could significantly alter treatment paradigms in the biopharmaceutical sector.